Potential hazard of pharmacokinetic interactions between lopinavir-ritonavir protease inhibitors and irinotecan.
Corona
Giuseppe
G
Vaccher
Emanuela
E
Cattarossi
Giulio
G
Sartor
Ivana
I
Toffoli
Giuseppe
G
D000284:Administration, Oral; D000328:Adult; D000972:Antineoplastic Agents, Phytogenic / Q000493:pharmacokinetics*; D023241:Antiretroviral Therapy, Highly Active / Q000379:methods; D002166:Camptothecin / Q000031:analogs & derivatives* / Q000493:pharmacokinetics; D004347:Drug Interactions; D015658:HIV Infections / Q000188:drug therapy*; D017320:HIV Protease Inhibitors / Q000008:administration & dosage*; D006801:Humans; D000077146:Irinotecan; D061466:Lopinavir; D008297:Male; D011744:Pyrimidinones / Q000008:administration & dosage*; D019438:Ritonavir / Q000008:administration & dosage*; D012514:Sarcoma, Kaposi / Q000188:drug therapy
D000972:Antineoplastic Agents, Phytogenic; D017320:HIV Protease Inhibitors; D011744:Pyrimidinones; D061466:Lopinavir; D000077146:Irinotecan; D019438:Ritonavir; D002166:Camptothecin